Expand all sections

Peginterferon alfa-2a

Pegasys

Extended indication Extension of indication to include treatment of Polycythaemia Vera (PV) and Essential thrombocytopen
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Peginterferon alfa-2a
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication Bacterial infections
Extended indication Extension of indication to include treatment of Polycythaemia Vera (PV) and Essential thrombocytopenia (ET)
Proprietary name Pegasys
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date November 2023
Expected Registration August 2024
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.